Cel­sius aims to cool down in­flam­ma­tion with new in­vestors and more phar­ma deals

Broad In­sti­tute spin­out Cel­sius Ther­a­peu­tics is turn­ing up the heat on the fi­nanc­ing front as it looks to ice the symp­toms of in­flam­ma­to­ry bow­el dis­ease.

The Cam­bridge, MA biotech has added $83 mil­lion in new fi­nanc­ing — a mix­ture of a Se­ries A ex­ten­sion and Se­ries B funds — to chase its vi­sion of pre­ci­sion ther­a­pies across au­toim­mune dis­eases and can­cer. The Third Rock- and GV-backed start­up, found­ed in 2018, brought in new in­vestors like Am­gen Ven­tures, Am­pli­tude Ven­tures and Fast Track Ini­tia­tive.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN